Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30001, 9700 RB Groningen, The Netherlands.
Essays Biochem. 2021 Jul 26;65(2):187-195. doi: 10.1042/EBC20200171.
Secreted recombinant proteins are of great significance for industry, healthcare and a sustainable bio-based economy. Consequently, there is an ever-increasing need for efficient production platforms to deliver such proteins in high amounts and high quality. Gram-positive bacteria, particularly bacilli such as Bacillus subtilis, are favored for the production of secreted industrial enzymes. Nevertheless, recombinant protein production in the B. subtilis cell factory can be very challenging due to bottlenecks in the general (Sec) secretion pathway as well as this bacterium's intrinsic capability to secrete a cocktail of highly potent proteases. This has placed another Gram-positive bacterium, Lactococcus lactis, in the focus of attention as an alternative, non-proteolytic, cell factory for secreted proteins. Here we review our current understanding of the secretion pathways exploited in B. subtilis and L. lactis to deliver proteins from their site of synthesis, the cytoplasm, into the fermentation broth. An advantage of this cell factory comparison is that it identifies opportunities for protein secretion pathway engineering to remove or bypass current production bottlenecks. Noteworthy new developments in cell factory engineering are the mini-Bacillus concept, highlighting potential advantages of massive genome minimization, and the application of thus far untapped 'non-classical' protein secretion routes. Altogether, it is foreseen that engineered lactococci will find future applications in the production of high-quality proteins at the relatively small pilot scale, while engineered bacilli will remain a favored choice for protein production in bulk.
分泌型重组蛋白在工业、医疗保健和可持续的生物基经济中具有重要意义。因此,人们越来越需要高效的生产平台,以大量、高质量地生产这些蛋白质。革兰氏阳性菌,特别是芽孢杆菌属的枯草芽孢杆菌,因其能够生产分泌型工业酶而受到青睐。然而,由于一般(Sec)分泌途径的瓶颈以及该细菌内在分泌高效蛋白酶混合物的能力,重组蛋白在枯草芽孢杆菌细胞工厂中的生产可能极具挑战性。这使得另一种革兰氏阳性菌——乳球菌 lactis 成为替代的、非蛋白水解的分泌蛋白细胞工厂的焦点。在这里,我们回顾了我们目前对枯草芽孢杆菌和乳球菌中利用的分泌途径的理解,这些途径将蛋白质从其合成部位——细胞质——输送到发酵液中。这种细胞工厂比较的一个优势是,它确定了蛋白质分泌途径工程的机会,可以消除或绕过当前的生产瓶颈。细胞工厂工程中值得注意的新进展是迷你芽孢杆菌概念,强调了大规模基因组最小化的潜在优势,以及迄今尚未开发的“非经典”蛋白质分泌途径的应用。总的来说,预计经过工程改造的乳球菌将在相对较小的中试规模下用于生产高质量的蛋白质,而经过工程改造的芽孢杆菌仍将是大规模生产蛋白质的首选。